Patient and disease characteristics
| Characteristics . | Overall, N = 624 . | Axi-cel, n = 344 . | Tisa-cel, n = 142 . | Liso-cel, n = 138 . | P value∗ . |
|---|---|---|---|---|---|
| Sex | .018 | ||||
| Male | 377 (61) | 219 (64) | 71 (50) | 87 (64) | |
| Female | 245 (39) | 125 (36) | 70 (50) | 50 (36) | |
| Age, y | <.001 | ||||
| ≤65 | 320 (51) | 228 (66) | 50 (35) | 42 (30) | |
| >65 | 304 (49) | 116 (34) | 92 (65) | 96 (70) | |
| Median (IQR) | 65 (56-73) | 62 (52-68) | 71 (62-77) | 71 (64-78) | <.001 |
| Performance status (KPS) | .001 | ||||
| ≥90 | 234 (38) | 140 (42) | 60 (43) | 34 (25) | |
| <90 | 380 (62) | 197 (58) | 79 (57) | 104 (75) | |
| LBCL subtype | .022 | ||||
| DLBCL, NOS | 515 (83) | 271 (79) | 124 (87) | 120 (87) | |
| HGBL | 64 (10) | 38 (11) | 14 (9.9) | 12 (8.7) | |
| Other† | 45 (7.2) | 35 (10) | 4 (2.8) | 6 (4.3) | |
| Double or triple hit | 81 (19) | 53 (23) | 13 (15) | 15 (13) | .036 |
| Cell of origin | .035 | ||||
| GCB | 281 (50) | 159 (53) | 53 (40) | 69 (53) | |
| Non-GCB | 281 (50) | 140 (47) | 79 (60) | 62 (47) | |
| Transformation status | .31 | ||||
| De novo | 427 (69) | 234 (69) | 98 (69) | 95 (69) | |
| Transformed FL | 121 (20) | 69 (20) | 22 (15) | 30 (22) | |
| Transformed from other | 69 (11) | 34 (10) | 22 (15) | 13 (9.4) | |
| Primary refractory | 265 (43) | 170 (50) | 48 (34) | 47 (35) | <.001 |
| Previous treatment lines‡ | <.001 | ||||
| <2 | 103 (17) | 67 (20) | 5 (3.5) | 31 (23) | |
| ≥2 | 509 (83) | 268 (80) | 137 (96) | 104 (77) | |
| Previous auto-HCT | 114 (18) | 60 (18) | 31 (22) | 23 (17) | .47 |
| Previous allo-HCT | 15 (2.4) | 7 (2) | 6 (4.2) | 2 (1.5) | .30 |
| Previous CAR T-cell therapy | 5 (0.8) | 3 (0.9) | 2 (1.4) | 0 (0) | .41 |
| CAR T-cell indication | <.001 | ||||
| Relapsed/refractory after ≥2 lines | 498 (80) | 265 (77) | 137 (96) | 96 (71) | |
| Relapsed >12 months after first line | 2 (0.3) | 0 (0) | 0 (0) | 2 (1.5) | |
| Relapsed ≤12 months after first line | 47 (7.6) | 28 (8.2) | 2 (1.4) | 17 (13) | |
| Refractory to first line | 67 (11) | 46 (13) | 3 (2.1) | 18 (13) | |
| Other | 6 (1.0) | 3 (0.9) | 0 (0) | 3 (2.2) | |
| Stage at apheresis | .14 | ||||
| ≤II | 137 (26) | 66 (23) | 32 (25) | 39 (32) | |
| >II | 400 (74) | 221 (77) | 97 (75) | 82 (68) | |
| Bulky disease at apheresis§ | 99 (16) | 71 (21) | 13 (9.6) | 15 (11) | .002 |
| CNS disease at apheresis | 47 (8) | 21 (6.6) | 9 (6.5) | 17 (13) | .043 |
| Bridging therapy|| | .027 | ||||
| No bridging | 210 (34) | 132 (38) | 40 (28) | 38 (28) | |
| Systemic therapy | 332 (53) | 166 (48) | 88 (62) | 78 (57) | |
| Nonsystemic therapy | 81 (13) | 45 (13) | 14 (9.9) | 22 (16) | |
| Response prelymphodepletion | .002 | ||||
| CR | 58 (9.5) | 23 (6.9) | 15 (11) | 20 (15) | |
| PR | 174 (29) | 103 (31) | 26 (19) | 45 (33) | |
| SD/PD | 377 (62) | 206 (62) | 99 (71) | 72 (53) | |
| LDH prelymphodepletion | .93 | ||||
| Normal (≤250 U/L) | 308 (54) | 163 (54) | 72 (53) | 73 (55) | |
| Elevated (>250 U/L) | 266 (46) | 141 (46) | 65 (47) | 60 (45) | |
| Lymphodepletion | .042 | ||||
| FluCy | 551 (88) | 297 (86) | 133 (94) | 121 (88) | |
| Bendamustine | 72 (12) | 47 (14) | 8 (5.7) | 17 (12) | |
| Apheresis to infusion (IQR), d | 39 (33-47) | 35 (28-43) | 43 (37-52) | 41 (37-51) | <.001 |
| OOS products | 20 (4) | 6 (2) | 4 (4) | 10 (11) | .004 |
| Treatment era | <.001 | ||||
| 2016-2020 | 222 (36) | 111 (32) | 83 (58) | 28 (20) | |
| 2021-2024 | 402 (64) | 233 (68) | 59 (42) | 110 (80) |
| Characteristics . | Overall, N = 624 . | Axi-cel, n = 344 . | Tisa-cel, n = 142 . | Liso-cel, n = 138 . | P value∗ . |
|---|---|---|---|---|---|
| Sex | .018 | ||||
| Male | 377 (61) | 219 (64) | 71 (50) | 87 (64) | |
| Female | 245 (39) | 125 (36) | 70 (50) | 50 (36) | |
| Age, y | <.001 | ||||
| ≤65 | 320 (51) | 228 (66) | 50 (35) | 42 (30) | |
| >65 | 304 (49) | 116 (34) | 92 (65) | 96 (70) | |
| Median (IQR) | 65 (56-73) | 62 (52-68) | 71 (62-77) | 71 (64-78) | <.001 |
| Performance status (KPS) | .001 | ||||
| ≥90 | 234 (38) | 140 (42) | 60 (43) | 34 (25) | |
| <90 | 380 (62) | 197 (58) | 79 (57) | 104 (75) | |
| LBCL subtype | .022 | ||||
| DLBCL, NOS | 515 (83) | 271 (79) | 124 (87) | 120 (87) | |
| HGBL | 64 (10) | 38 (11) | 14 (9.9) | 12 (8.7) | |
| Other† | 45 (7.2) | 35 (10) | 4 (2.8) | 6 (4.3) | |
| Double or triple hit | 81 (19) | 53 (23) | 13 (15) | 15 (13) | .036 |
| Cell of origin | .035 | ||||
| GCB | 281 (50) | 159 (53) | 53 (40) | 69 (53) | |
| Non-GCB | 281 (50) | 140 (47) | 79 (60) | 62 (47) | |
| Transformation status | .31 | ||||
| De novo | 427 (69) | 234 (69) | 98 (69) | 95 (69) | |
| Transformed FL | 121 (20) | 69 (20) | 22 (15) | 30 (22) | |
| Transformed from other | 69 (11) | 34 (10) | 22 (15) | 13 (9.4) | |
| Primary refractory | 265 (43) | 170 (50) | 48 (34) | 47 (35) | <.001 |
| Previous treatment lines‡ | <.001 | ||||
| <2 | 103 (17) | 67 (20) | 5 (3.5) | 31 (23) | |
| ≥2 | 509 (83) | 268 (80) | 137 (96) | 104 (77) | |
| Previous auto-HCT | 114 (18) | 60 (18) | 31 (22) | 23 (17) | .47 |
| Previous allo-HCT | 15 (2.4) | 7 (2) | 6 (4.2) | 2 (1.5) | .30 |
| Previous CAR T-cell therapy | 5 (0.8) | 3 (0.9) | 2 (1.4) | 0 (0) | .41 |
| CAR T-cell indication | <.001 | ||||
| Relapsed/refractory after ≥2 lines | 498 (80) | 265 (77) | 137 (96) | 96 (71) | |
| Relapsed >12 months after first line | 2 (0.3) | 0 (0) | 0 (0) | 2 (1.5) | |
| Relapsed ≤12 months after first line | 47 (7.6) | 28 (8.2) | 2 (1.4) | 17 (13) | |
| Refractory to first line | 67 (11) | 46 (13) | 3 (2.1) | 18 (13) | |
| Other | 6 (1.0) | 3 (0.9) | 0 (0) | 3 (2.2) | |
| Stage at apheresis | .14 | ||||
| ≤II | 137 (26) | 66 (23) | 32 (25) | 39 (32) | |
| >II | 400 (74) | 221 (77) | 97 (75) | 82 (68) | |
| Bulky disease at apheresis§ | 99 (16) | 71 (21) | 13 (9.6) | 15 (11) | .002 |
| CNS disease at apheresis | 47 (8) | 21 (6.6) | 9 (6.5) | 17 (13) | .043 |
| Bridging therapy|| | .027 | ||||
| No bridging | 210 (34) | 132 (38) | 40 (28) | 38 (28) | |
| Systemic therapy | 332 (53) | 166 (48) | 88 (62) | 78 (57) | |
| Nonsystemic therapy | 81 (13) | 45 (13) | 14 (9.9) | 22 (16) | |
| Response prelymphodepletion | .002 | ||||
| CR | 58 (9.5) | 23 (6.9) | 15 (11) | 20 (15) | |
| PR | 174 (29) | 103 (31) | 26 (19) | 45 (33) | |
| SD/PD | 377 (62) | 206 (62) | 99 (71) | 72 (53) | |
| LDH prelymphodepletion | .93 | ||||
| Normal (≤250 U/L) | 308 (54) | 163 (54) | 72 (53) | 73 (55) | |
| Elevated (>250 U/L) | 266 (46) | 141 (46) | 65 (47) | 60 (45) | |
| Lymphodepletion | .042 | ||||
| FluCy | 551 (88) | 297 (86) | 133 (94) | 121 (88) | |
| Bendamustine | 72 (12) | 47 (14) | 8 (5.7) | 17 (12) | |
| Apheresis to infusion (IQR), d | 39 (33-47) | 35 (28-43) | 43 (37-52) | 41 (37-51) | <.001 |
| OOS products | 20 (4) | 6 (2) | 4 (4) | 10 (11) | .004 |
| Treatment era | <.001 | ||||
| 2016-2020 | 222 (36) | 111 (32) | 83 (58) | 28 (20) | |
| 2021-2024 | 402 (64) | 233 (68) | 59 (42) | 110 (80) |
Data are presented as n (%) unless otherwise specified. Values in bold are statistically significant.
allo-HCT, allogeneic hematopoietic cell transplantation; auto-HCT, autologous hematopoietic cell transplantation; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; FluCy, fludarabine + cyclophosphamide; HGBL, high-grade B-cell lymphoma; NOS, not otherwise specified; PD, progressive disease; PR, partial response; SD, stable disease.
Categorical variables were compared using Pearson χ2 test or Fisher exact test; continuous variables, with the Kruskal-Wallis rank sum test.
Includes 28 patients with primary mediastinal B-cell lymphoma, 7 with T-cell/histiocyte-rich LBCL, 5 with Epstein-Barr virus–positive DLBCL, 3 with leg type of primary cutaneous DLBCL, 1 with intravascular LBCL, and 1 with anaplastic lymphoma kinase–positive large B-cell lymphoma.
Includes all therapies administered before apheresis, including disease-holding therapy.
Bulky disease is defined as any mass ≥10 cm or more than one-third of mediastinum by tomodensitometry or positron emission tomography scan.
Systemic therapy includes all chemotherapies and course of steroids. Nonsystemic therapy includes radiation therapy and surgical debulking.